Literature DB >> 16636677

SLP65 deficiency results in perpetual V(D)J recombinase activity in pre-B-lymphoblastic leukemia and B-cell lymphoma cells.

M Sprangers1, N Feldhahn, S Liedtke, H Jumaa, R Siebert, M Müschen.   

Abstract

Perpetual V(D)J recombinase activity involving multiple DNA double-strand break events in B-cell lineage leukemia and lymphoma cells may introduce secondary genetic aberrations leading towards malignant progression. Here, we investigated defective negative feedback signaling through the (pre-) B-cell receptor as a possible reason for deregulated V(D)J recombinase activity in B-cell malignancy. On studying 28 cases of pre-B-lymphoblastic leukemia and 27 B-cell lymphomas, expression of the (pre-) B-cell receptor-related linker molecule SLP65 (SH2 domain-containing lymphocyte protein of 65 kDa) was found to be defective in seven and five cases, respectively. SLP65 deficiency correlates with RAG1/2 expression and unremitting V(H) gene rearrangement activity. Reconstitution of SLP65 expression in SLP65-deficient leukemia and lymphoma cells results in downregulation of RAG1/2 expression and prevents both de novo V(H)-DJ(H) rearrangements and secondary V(H) replacement. We conclude that iterative V(H) gene rearrangement represents a frequent feature in B-lymphoid malignancy, which can be attributed to SLP65 deficiency in many cases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16636677     DOI: 10.1038/sj.onc.1209520

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  6 in total

Review 1.  Autoimmunity checkpoints as therapeutic targets in B cell malignancies.

Authors:  Markus Müschen
Journal:  Nat Rev Cancer       Date:  2018-01-05       Impact factor: 60.716

2.  The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.

Authors:  Stephen E Spurgeon; Greg Coffey; Luke B Fletcher; Russell Burke; Jeffrey W Tyner; Brian J Druker; Andreas Betz; Francis DeGuzman; Yvonne Pak; Dale Baker; Anjali Pandey; Stanley J Hollenbach; Uma Sinha; Marc M Loriaux
Journal:  J Pharmacol Exp Ther       Date:  2012-12-07       Impact factor: 4.030

3.  Pre-B cell receptor signaling in acute lymphoblastic leukemia.

Authors:  Rahul Nahar; Markus Müschen
Journal:  Cell Cycle       Date:  2009-12-09       Impact factor: 4.534

4.  BLNK suppresses pre-B-cell leukemogenesis through inhibition of JAK3.

Authors:  Joji Nakayama; Mutsumi Yamamoto; Katsuhiko Hayashi; Hitoshi Satoh; Kenji Bundo; Masato Kubo; Ryo Goitsuka; Michael A Farrar; Daisuke Kitamura
Journal:  Blood       Date:  2008-12-01       Impact factor: 22.113

5.  The Myc-miR-17-92 axis amplifies B-cell receptor signaling via inhibition of ITIM proteins: a novel lymphomagenic feed-forward loop.

Authors:  James N Psathas; Patrick J Doonan; Pichai Raman; Bruce D Freedman; Andy J Minn; Andrei Thomas-Tikhonenko
Journal:  Blood       Date:  2013-10-29       Impact factor: 22.113

6.  The Clonal Diversity of Peripheral B Cell Receptor Immune Repertoire Impaired by Residual Malignant B Cells Predicts Treatment Efficacy in B Cell Lymphoma Patients.

Authors:  Meng Wu; Jing Zhang; Yi Wang; Lan Mi; Xiaopei Wang; Weiping Liu; Jie Fu; Haifeng Song; Yuqin Song; Jun Zhu
Journal:  Cancers (Basel)       Date:  2022-09-23       Impact factor: 6.575

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.